Latest Breaking News On - Frida dunger johnsson - Page 1 : comparemela.com

World Psoriasis Day 2023: Access for All

Tildrakizumab Improved Quality of Life, Skin Symptoms in Plaque Psoriasis Patients

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for patients who have psoriasis.

Almirall's Ilumetri shown to improve well-being of patients with plaque psoriasis

Almirall: Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis

Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis

At the 25th World Congress of Dermatology Tildrakizumab also significantly improved skin symptoms and quality of life in patients with moderate to severe plaque psoriasis after 28 weeks in a real-world setting and with a safety profile consistent with randomized phase III clinical trials1,2 Almirall has shown for the first time that the wellbeing of patients with moderate to severe plaque psoriasis at baseline was comparable to the level of wellbeing found in other diseases3 such as breast cancer4 Preliminary results of the POSITIVE study demonstrate the company s commitment to addressing unmet needs in the treatment of patients with psoriasis